Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model

Ercan, Cihangir Mutlu; Kayaalp, Oya; Cengiz, Mehmet Ali; Keskin, Uğur; Yumuşak, Nihat; Aydoğan, Ümit; İde, Tayfun; Ergün, Ali

doi:10.1007/s00404-014-3524-x

Cited by 24 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cabergoline also inhibited the growth of established endometriotic lesions in a rat endometriosis model. Its anti-angiogenic action is mediated by inhibition of VEGFR-2 phosphorylation [ 53 ]. Compared to luteinizing hormone releasing hormone (LHRH) agonist, cabergoline (dostinex) yields better resulted in decreasing the size of endometrioma by vaginal ultrasound in endometriosis patients in a prospective randomized study [ 54 ].…”

Section: Resultsmentioning

confidence: 99%

Anti‐Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms

Zheng

Cao²,

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Endometriosis is caused by the growth or infiltration of endometrial tissues outside of the endometrium and myometrium. Symptoms include pain and infertility. Surgery and hormonal therapy are widely used in Western medicine for the treatment of endometriosis; however, the side effects associated with this practice include disease recurrence and menopause, which can severely influence quality of life. Angiogenesis is the main biological mechanism underlying the development of endometriosis. Numerous natural products and Chinese medicines with potent anti-angiogenic effects have been investigated, and the molecular basis underlying their therapeutic effects in endometriosis has been explored. This review aims to describe natural products and compounds that suppress angiogenesis associated with endometriosis and to assess their diverse molecular mechanisms of action. Furthermore, this review provides a source of information relating to alternative and complementary therapeutic products that mediate anti-angiogenesis. An extensive review of the literature and electronic databases, such as the China National Knowledge Infrastructure, PubMed, and Embase, was conducted using the keywords ‘endometriosis,' ‘traditional Chinese medicine,' ‘Chinese herbal medicine,' ‘natural compounds,' and ‘anti-angiogenic' therapy. Anti-angiogenic therapy is an emerging strategy for the treatment of endometriosis. Natural anti-angiogenic products and Chinese medicines provide several beneficial clinical effects, including pain relief. In this review, we summarize clinical trials and experimental studies of endometriosis using natural products and Chinese medicines. In particular, we focus on anti-angiogenic products and alternative and complementary medicines for the treatment of endometriosis and additionally examine their therapeutic efficacy and mechanisms of action. Anti-angiogenic natural products and/or compounds provide a new approach for the treatment of endometriosis. Future work will require randomized trials with larger numbers of subjects, as well as long-term follow-up to confirm the findings described here.

show abstract

Section: Resultsmentioning

confidence: 99%

Anti‐Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms

Zheng

Cao²,

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Based on this evidence, identification and quantification of dopamine receptor type 2 might represent a novel molecular target for the treatment of endometriosis ( 53 ). In rat models, dopamine agonists have shown promising results, since bromocriptine ( 54 ), cabergoline ( 54 , 55 ) and quinagolide ( 56 ) have been reported to significantly reduce endometriotic loci size and volume ( 54 – 56 ) following one-month treatment, dopamine agonists being as effective as GnRH agonists in inducing the involution of experimental endometriotic implants in rats ( 55 ). In women with endometriosis and serum PRL levels of greater than 30 ng/ml, quinagolide 25 to 75 μg/day has been found to reduce the surface of endometriotic lesions by 69.5% after 4 months of treatment ( 57 ).…”

Section: Prl Impact In Endometriosismentioning

confidence: 99%

The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology

et al. 2020

View full text Add to dashboard Cite

Over the last years, increasing evidence has focused on crucial pathogenetic role of PRL on malignant, premalignant and benign uterine diseases. Studies in animals and humans have documented that PRL receptors (PRL-Rs) are widely expressed on uterine cells and that PRL is directly synthesized by the endometrium under the stimulatory action of progesterone. Uterine PRL secretion is finely modulated by autocrine/paracrine mechanisms which do not depend on the same control factors implied in the regulation of PRL secretion from pituitary. On the other hand, PRL is synthesized also in the myometrium and directly promotes uterine smooth muscle cell growth and proliferation. Therefore, PRL and PRL-Rs appear to play an important role for the activation of signaling pathways involved in uterine cancers and preneoplastic lesions. Circulating PRL levels are reportedly increased in patients with cervical or endometrial cancers, as well as uterine premalignant lesions, and might be used as discriminative biomarker in patients with uterine cancers. Similarly, increased PRL levels have been implicated in the endometriosis-induced infertility, albeit a clear a causative role for PRL in the pathogenesis of endometriosis is yet to be demonstrated. This evidence has suggested the potential application of dopamine agonists in the therapeutic algorithm of women with malignant, premalignant and benign uterine lesions. This review focuses on the role of PRL as tumorigenic factor for uterus and the outcome of medical treatment with dopamine agonists in patients with malignant and benign uterine disease.

show abstract

“…На модели животных было показано, что агонисты дофаминовых рецепторов (D 2 ) могут подавлять ангиоге-нез в опухолях, инактивируя сигналы рецептора VEGF [40,41]. Описано, что агонисты дофамина могут снижать активность VEGF и подавлять неоангиогенез, в том числе в очагах эндометриоза.…”

Section: возможности терапии агонистами дофамина в экспериментальных unclassified

“…После окончания лечения с применением агонистов дофамина в обеих группах отмечалось угнетение неоангио-генеза по сравнению с контрольной группой [40,41]. Сле-дует отметить, что по таким показателям, как уменьшение размеров очагов эндометриоза, снижение уровней VEGF мРНК и VEGFR 2 мРНК, неэрголиновые агонисты дофа-мина показали такую же эффективность, как и эрголино-вые, что свидетельствует о возможности применения обе-их групп препаратов для лечения больных НГЭ [40].…”

Section: производные трициклических бензогуанолинов (неэр-голиновые)unclassified

See 1 more Smart Citation

The significance of prolactin in the pathogenesis of genital endometriosis and the possibilities of dopamine agonist therapy

Molotkov¹,

Yarmolinskaya²

2015

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model

Abstract: Dopamine agonists are as effective as GnRH agonists in the regression of experimental endometriotic implants in rats. Further trials are needed to elucidate the pathways affected by dopamine agonists.

Cited by 24 publications

References 33 publications

Anti‐Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms

Anti‐Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms

The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology

The significance of prolactin in the pathogenesis of genital endometriosis and the possibilities of dopamine agonist therapy

Contact Info

Product

Resources

About